TW200626176A - Pharmaceutical compositions for increasing cholesterol efflux from cells of a mammalian subject - Google Patents
Pharmaceutical compositions for increasing cholesterol efflux from cells of a mammalian subjectInfo
- Publication number
- TW200626176A TW200626176A TW095113205A TW95113205A TW200626176A TW 200626176 A TW200626176 A TW 200626176A TW 095113205 A TW095113205 A TW 095113205A TW 95113205 A TW95113205 A TW 95113205A TW 200626176 A TW200626176 A TW 200626176A
- Authority
- TW
- Taiwan
- Prior art keywords
- abc1
- cholesterol efflux
- methods
- pharmaceutical compositions
- mammalian subject
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 6
- 235000012000 cholesterol Nutrition 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 abstract 7
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 abstract 7
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- -1 host cells Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Addiction (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Abstract
The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention provides recombinant vectors, host cells, and pharmaceutical compositions comprising ABC1 polynucleotides, as well as methods for producing ABC1 polypeptides. The invention also provides methods for the diagnosis, treatrnent, amelioration, and/or prevention of diseases associated with decreased cholesterol efflux and/or low HDL. The present invention further provides methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether the compound modulates ABC1-dependent cholesterol efflux.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14026499P | 1999-06-18 | 1999-06-18 | |
| US15387299P | 1999-09-14 | 1999-09-14 | |
| US16657399P | 1999-11-19 | 1999-11-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200626176A true TW200626176A (en) | 2006-08-01 |
| TWI304737B TWI304737B (en) | 2009-01-01 |
Family
ID=27385472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089111924A TWI259205B (en) | 1999-06-18 | 2000-08-25 | Polynucleotides having ABC1 promoter activity, recombinant vectors, host cells and kits comprising the same, and method for screening a test compound of ABC1 expression modulating activity |
| TW095113205A TWI304737B (en) | 1999-06-18 | 2000-08-25 | Pharmaceutical compositions for increasing cholesterol efflux from cells of a mammalian subject |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089111924A TWI259205B (en) | 1999-06-18 | 2000-08-25 | Polynucleotides having ABC1 promoter activity, recombinant vectors, host cells and kits comprising the same, and method for screening a test compound of ABC1 expression modulating activity |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1190065A2 (en) |
| JP (4) | JP2003508031A (en) |
| KR (2) | KR100476519B1 (en) |
| CN (2) | CN1379817A (en) |
| AR (2) | AR024391A1 (en) |
| AT (1) | ATE422545T1 (en) |
| AU (3) | AU5743400A (en) |
| BR (2) | BR0011696A (en) |
| CA (2) | CA2375781A1 (en) |
| DE (1) | DE60041545D1 (en) |
| HK (2) | HK1046427A1 (en) |
| IL (2) | IL147022A0 (en) |
| MX (2) | MXPA01013175A (en) |
| NO (2) | NO20016121L (en) |
| NZ (3) | NZ529785A (en) |
| SG (2) | SG121853A1 (en) |
| TR (2) | TR200200440T2 (en) |
| TW (2) | TWI259205B (en) |
| WO (2) | WO2000078972A2 (en) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| US6617122B1 (en) | 1999-03-15 | 2003-09-09 | Xenon Genetics, Inc. | Process for identifying modulators of ABC1 activity |
| JP2004500332A (en) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Compositions and methods for increasing HDL cholesterol levels |
| WO2001015676A2 (en) * | 1999-09-01 | 2001-03-08 | University Of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| WO2001083746A2 (en) | 2000-05-02 | 2001-11-08 | Aventis Pharma S.A. | Regulatory nucleic acid sequences of the abc1 gene |
| EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| AU2002317093A1 (en) * | 2001-07-03 | 2003-01-21 | University Of British Columbia | Screening processes for agents modulating cholesterol levels |
| WO2003033023A1 (en) * | 2001-10-12 | 2003-04-24 | Grelan Pharmaceutical Co., Ltd. | Drugs ameliorating hypo-hdl cholesterolemia |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| JP5082033B2 (en) | 2001-12-21 | 2012-11-28 | エグゼリクシス パテント カンパニー エルエルシー | LXR modulator |
| EP1465882B1 (en) | 2001-12-21 | 2011-08-24 | X-Ceptor Therapeutics, Inc. | Hetrocyclic modulators of nuclear receptors |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| ATE496893T1 (en) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS MEDICATIONS |
| JP4679517B2 (en) | 2003-07-23 | 2011-04-27 | エグゼリクシス， インコーポレイテッド | Azepine derivatives as drugs |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| EP3613767A1 (en) | 2005-05-18 | 2020-02-26 | Ablynx N.V. | Improved nanobodiestm against tumor cecrosis factor-alpha |
| KR101414438B1 (en) | 2005-05-20 | 2014-07-10 | 아블린쓰 엔.브이. | Single domain vhh antibodies against von willebrand factor |
| ES2525217T3 (en) | 2005-06-27 | 2014-12-19 | Exelixis Patent Company Llc | LXR modulators based on imidazole |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| EP2070919B1 (en) | 2006-11-24 | 2012-10-10 | Hykes Laboratories LLC | Spiroquinone compound and pharmaceutical composition |
| EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| EP2557090A3 (en) | 2006-12-19 | 2013-05-29 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| AU2008328781A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| CA2717015A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| CN102056945A (en) | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | Amino acid sequences directed against the Notch pathways and uses thereof |
| EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| DK2414521T3 (en) * | 2009-03-31 | 2017-01-30 | Massachusetts Gen Hospital | Regulation of miR-33 microRNAs in the treatment of cholesterol-related diseases |
| KR101470690B1 (en) | 2009-04-10 | 2014-12-10 | 아블린쓰 엔.브이. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| CN102648184B (en) | 2009-05-28 | 2015-09-30 | 埃克塞利希斯专利有限责任公司 | LXR conditioning agent |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| CU24111B1 (en) | 2010-11-08 | 2015-08-27 | Novartis Ag | POLYPEPTIDES THAT LINK TO CXCR2 |
| AR088728A1 (en) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | LXR MODULATORS AS IMIDAZOL PRODROGA |
| WO2012175740A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Immunoglobulin single variable domains directed against ige |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| WO2013188740A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
| EP2967073B9 (en) | 2013-03-15 | 2019-04-10 | Bristol-Myers Squibb Company | Lxr modulators |
| CN105209039B (en) | 2013-03-15 | 2018-06-22 | 百时美施贵宝公司 | LXR conditioning agents |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| EP3380517B1 (en) | 2015-11-27 | 2021-08-04 | Ablynx NV | Polypeptides inhibiting cd40l |
| EP3512880A1 (en) | 2016-09-15 | 2019-07-24 | Ablynx NV | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| CN117700549A (en) | 2016-11-16 | 2024-03-15 | 埃博灵克斯股份有限公司 | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| TWI811220B (en) | 2017-06-02 | 2023-08-11 | 比利時商艾伯林克斯公司 | Aggrecan binding immunoglobulins |
| US12129308B2 (en) | 2017-06-02 | 2024-10-29 | Merck Patent Gmbh | MMP13 binding immunoglobulins |
| RS66191B1 (en) | 2017-06-02 | 2024-12-31 | Merck Patent Gmbh | Adamts binding immunoglobulins |
| KR20250005464A (en) | 2017-06-02 | 2025-01-09 | 메르크 파텐트 게엠베하 | Polypeptides binding adamts5, mmp13 and aggrecan |
| KR20230019812A (en) * | 2020-03-06 | 2023-02-09 | 엔돌리틱스 테크놀로지, 인크. | Compositions and methods for the treatment of intracellular bacterial infections |
| CN115433733B (en) | 2021-06-04 | 2025-12-12 | 生物岛实验室 | Polypeptides translated from circular RNA Circ-ACE2 and their applications |
| CN114369162B (en) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | Antibodies and uses thereof |
| EP4556022A1 (en) | 2022-07-14 | 2025-05-21 | Bio-Thera Solutions, Ltd. | Anti-nectin-4 antibody and use thereof |
| AU2023313033A1 (en) | 2022-07-27 | 2025-03-13 | Ablynx Nv | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| KR20250151445A (en) | 2023-02-17 | 2025-10-21 | 아블린쓰 엔.브이. | Polypeptide that binds to the neonatal FC receptor |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| CN118027196B (en) | 2023-06-25 | 2025-12-02 | 合肥天港免疫药物有限公司 | Anti-CD3 antibodies and their applications |
| AR133188A1 (en) | 2023-07-05 | 2025-09-03 | Ablynx Nv | Improved FcRn antagonists for the treatment of IgG-related diseases and disorders |
| TW202525843A (en) | 2023-09-04 | 2025-07-01 | 法商賽諾菲公司 | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| AR133774A1 (en) | 2023-09-11 | 2025-10-29 | Novo Nordisk As | ANTI-IL-6 DOMAIN ANTIBODIES |
| TW202532432A (en) | 2023-09-22 | 2025-08-16 | 比利時商艾伯霖克斯公司 | Bi- and multivalent albumin binders |
| TW202543670A (en) | 2023-12-22 | 2025-11-16 | 比利時商艾伯霖克斯公司 | Protein-based conjugation carriers for intranuclear delivery |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025207946A1 (en) | 2024-03-28 | 2025-10-02 | Genzyme Corporation | Polypeptides binding to a specific epitope of the transferrin receptor 1 |
| US20260007757A1 (en) | 2024-06-18 | 2026-01-08 | Ablynx Nv | Antibody-recruiting molecules |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001083746A2 (en) * | 2000-05-02 | 2001-11-08 | Aventis Pharma S.A. | Regulatory nucleic acid sequences of the abc1 gene |
-
2000
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/en active IP Right Grant
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 HK HK02107131.3A patent/HK1046427A1/en unknown
- 2000-06-16 DE DE60041545T patent/DE60041545D1/en not_active Expired - Fee Related
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/en unknown
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/en active Pending
- 2000-06-16 AR ARP000103012A patent/AR024391A1/en unknown
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/en active Pending
- 2000-06-16 AR ARP000103013A patent/AR024576A1/en unknown
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/en unknown
- 2000-06-16 CN CN00809163A patent/CN1379817A/en active Pending
- 2000-06-16 AT AT00942914T patent/ATE422545T1/en not_active IP Right Cessation
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/en not_active IP Right Cessation
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/en unknown
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Ceased
- 2000-06-16 IL IL14702200A patent/IL147022A0/en unknown
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/en not_active Application Discontinuation
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/en not_active Expired - Fee Related
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 CN CNB008091641A patent/CN100513570C/en not_active Expired - Fee Related
- 2000-06-16 HK HK02108234.7A patent/HK1046708A1/en unknown
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/en not_active Ceased
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 IL IL14702100A patent/IL147021A0/en unknown
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Ceased
- 2000-08-25 TW TW089111924A patent/TWI259205B/en not_active IP Right Cessation
- 2000-08-25 TW TW095113205A patent/TWI304737B/en active
-
2001
- 2001-12-14 NO NO20016121A patent/NO20016121L/en not_active Application Discontinuation
- 2001-12-14 NO NO20016114A patent/NO20016114L/en unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/en not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200626176A (en) | Pharmaceutical compositions for increasing cholesterol efflux from cells of a mammalian subject | |
| NZ323795A (en) | Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides | |
| WO1998031818A3 (en) | Tace-like and matrilysin-like polypeptides | |
| WO1997035989A3 (en) | Cyclic nucleotide phosphodiesterase | |
| WO2001055308A3 (en) | Nucleic acids, proteins, and antibodies | |
| WO2001055306A3 (en) | Nucleic acids, proteins, and antibodies | |
| AU2003240631A1 (en) | A t cell subpopulation regulating gut immunity | |
| WO1999001551A3 (en) | Novel inhibitor of cellular proliferation | |
| EP0897011A3 (en) | Novel arginine deiminase | |
| WO1999063094A3 (en) | Nucleotide and protein sequences of gpr1 and methods based thereon | |
| BG106842A (en) | Human heparanase-related polypeptide and nucleic acid | |
| Fujita et al. | The activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice immunized with type II collagen | |
| WO2000007545A8 (en) | Apoptosis proteins | |
| WO2001055162A8 (en) | Nucleic acids, proteins, and antibodies | |
| RU2004124375A (en) | APPROACH TO DETERMINATION OF FACTORS THAT MODULATE INGAP EXPRESSION | |
| WO2001055305A8 (en) | Nucleic acids, proteins, and antibodies |